Global CRO leader Covance is a leading full‑service CRO with a broad track record across top pharma and biotech programs, highlighting potential for expanding strategic partnerships, multi‑drug development programs, and long‑term outsourcing engagements.

Full‑spectrum capabilities As the world’s most comprehensive drug development CRO, Covance offers nonclinical, clinical, and specialized services (including cell and gene therapy focus) that can unlock upsell opportunities across the entire development timeline for existing clients seeking a single vendor ecosystem.

Innovation and tech Investments in assets and advanced tech stack (Tableau, Kubernetes, Jira, Splunk, AEM) signal a modernization trajectory that can be leveraged to offer data‑driven trial optimization, faster study delivery, and scalable cloud‑native solutions to prospective clients.

Awards and credibility Industry recognition (CRO of the Year 2020, Markie awards, quality awards) enhances credibility when pursuing new logos, expanded scopes with current customers, and competitive distinctions in bids.

Growth signals Recent expansions in preclinical oncology facilities and leadership in cell and gene therapy indicate growing capacity and specialization, presenting cross‑sell potential to biopharma companies accelerating oncology and advanced therapy programs.